p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy (Q38472664)

3 September 2017

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy (English)

1 reference

3 September 2017

0 references

1 reference

1 reference

Huang A

1

1 reference

3 September 2017

Gandour-Edwards R

2

1 reference

3 September 2017

Rosenthal SA

3

1 reference

3 September 2017

Siders DB

4

1 reference

3 September 2017

Deitch AD

5

1 reference

3 September 2017

White RW

6

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 February 1998

1 reference

3 September 2017

1 reference

3 September 2017

51

1 reference

3 September 2017

2

1 reference

3 September 2017

346-351

1 reference

3 September 2017

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Wild-type p53 is a cell cycle checkpoint determinant following irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Bcl-2 and the regulation of programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

p53 oncogene mutations in three human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

In vitro radiation sensitivity of the LNCaP prostatic tumor cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900636-5

7 January 2021

10.1016/S0090-4295(97)00636-5

Identifiers

DOI

1 reference

3 September 2017

1 reference